Informations

01 Oncology Frontier: With Lerociclib now approved in China, what impact will it have on the treatment of HR+/HER2– advanced breast cancer? Prof. Jing Cheng: For adult patients with HR+/HER2–…

Editor’s Note: As a standard treatment for hormone receptor–positive, HER2–negative metastatic breast cancer (HR+/HER2- MBC), CDK4/6 inhibitors (CDK4/6i) have significantly improved therapeutic outcomes and expanded treatment options. However, developing next-generation…

Editor’s Note: CDK4/6 inhibitors (CDK4/6i) have become an important therapeutic option for hormone receptor–positive, HER2–negative (HR+/HER2-) breast cancer, yet there remains room for improvement in efficacy and safety.  Recently, the…

01 What distinguishes lerociclib’s molecular design and mechanism from traditional CDK4/6 inhibitors? Professor Sun Tao: As we know, CDK4/6 inhibitors combined with endocrine therapy are established as a standard first-line…

Editor’s Note: The China National Medical Products Administration (NMPA) has officially approved the novel CDK4/6 inhibitor (CDK4/6i) Lerociclib for two indications in adult patients with hormone receptor–positive, HER2–negative (HR+/HER2-) locally…

Editor’s Note: CDK4/6 inhibitors (CDK4/6i) play a pivotal role in the treatment of HR+/HER2– advanced breast cancer (ABC). However, their efficacy and safety profiles vary across different agents. There remains…

Introduction CDK4/6 inhibitors (CDK4/6i) have become the cornerstone of standard therapy for patients with HR+/HER2- advanced breast cancer. However, differences in efficacy and safety profiles exist among currently approved CDK4/6…

Editor’s Note: On May 29, 2025, China’s National Medical Products Administration (NMPA) simultaneously approved Lerociclib (汝佳宁®, Lerociclib) for two indications in adult patients with hormone receptor–positive (HR+), human epidermal growth…